Nkarta's NKX019 Hits 83% Myositis, 86% SSc Responses With Zero CRS/ICANS/GvHD
NKTX is trading near its 52-week low of $1.48 (2.0% below the low) on elevated volume (2.6× avg).
Summary
Nkarta reported initial NKX019 data showing 83% myositis and 86% systemic sclerosis response rates at the 4 billion-cell dose, with no CRS, ICANS, IEC-HS or GvHD across 40 patients. Dosing is now being compressed and FDA talks on a registrational path are in preparation.
Key Events · Product Development and Regulatory · NKTX
-
Initial NKX019 Efficacy Data Released
At 4 billion cells/dose, 5 of 6 myositis patients (83%) with at least three months of follow-up achieved moderate or major TIS responses; 6 of 7 systemic sclerosis patients (86%) achieved rCRISS-25 and 5 of 7 (71%) rCRISS-50 by Day 90.
-
Clean Safety Across 40 Patients
Across five autoimmune indications and three dose levels, there were no cases of CRS, ICANS, IEC-HS or GvHD, no treatment discontinuations due to adverse events and no deaths; infusion-related reactions occurred in 5 patients (12.5%), mostly Grade 1.
-
Dosing Compressed, 6B Dose Planned
Host T-cell recovery before the Day 7 dose prompted a protocol amendment to dose on Days 0, 2 and 4, with a planned 6 billion-cell evaluation alongside the 4 billion-cell cohort.
-
FDA Talks and 1H 2027 Milestones
Nkarta anticipates upcoming FDA interactions on registrational pathways in myositis and systemic sclerosis, with additional follow-up and a registrational dose plan (4B vs 6B) expected in the first half of 2027.
Analysis · NKTX · Life Sciences
Here is the first look at NKX019's actual clinical results in autoimmune disease, and they are strong on both axes that matter for a cell therapy: efficacy and safety. At the 4 billion-cell dose, 5 of 6 myositis patients (83%) with at least three months of follow-up hit moderate-or-major TIS responses, while 6 of 7 systemic sclerosis patients (86%) reached rCRISS-25, with 5 of 7 (71%) at rCRISS-50 and a median 15-point mRSS drop by Day 90. Just as important, across 40 treated patients there were no cases of CRS, ICANS, IEC-HS or GvHD and no discontinuations or deaths — the toxicities that make rival CAR-T therapies hospital-bound. That safety profile is what supports outpatient, community-rheumatologist administration, the commercial thesis here. Protocols have been amended to compress dosing to Days 0, 2 and 4, and the company will test 6 billion cells, with FDA registrational discussions upcoming and a dose-selection plan in 1H 2027. Caveats: these are small, early, open-label numbers with a September 18, 2026 cutoff, and some patients received outside immunomodulatory therapy. With the stock near its 52-week low, the readout is the clearest re-rating event the program has had.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NKTX was trading at $1.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $124M. The 52-week trading range was $1.48 to $3.72. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.